CLINICAL RESEARCH: CLINICAL TRIAL
Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure
A Multicenter, Randomized, Controlled Trial
Sophia Zoungas, MBBS*,
Barry P. McGrath, MBBS, MD*,*,
Pauline Branley, BMed, PhD ,
Peter G. Kerr, MBBS, PhD ,
Christine Muske, BSci(Nurs),
Rory Wolfe, PhD,
Robert C. Atkins, MBBS, DSc,
Kathy Nicholls, MBBS, MD ,
Margaret Fraenkel, BMBS, PhD||,
Brian G. Hutchison, MBBS¶,
Robert Walker, MBChB, MD# and
John J. McNeil, MBBS, PhD
* Department of Vascular Sciences and Medicine, Centre for Vascular Health, Monash University, Dandenong Hospital, Dandenong, Victoria, Australia
Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
Department of Nephrology, Royal Melbourne Hospital, Parkville, and Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
|| Department of Nephrology, Austin Health, Heidelberg, Victoria, Australia
¶ Department of Nephrology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
# Department of Nephrology, Dunedin Hospital, Dunedin, New Zealand
Manuscript received June 22, 2005;
revised manuscript received September 30, 2005,
accepted October 3, 2005.
* Reprint requests and correspondence: Prof. Barry P. McGrath, Department of Vascular Sciences and Medicine, Monash University, Dandenong Hospital, Dandenong 3175, Victoria, Australia. (Email: barry.mcgrath{at}med.monash.edu.au).
OBJECTIVES: The Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) aimed to establish whether high-dose folic acid would slow the progression of atherosclerosis and reduce cardiovascular events in patients with chronic renal failure (CRF).
BACKGROUND: Hyperhomocysteinemia is a potential contributor to the high rates of cardiovascular morbidity and mortality in patients with CRF.
METHODS: A total of 315 subjects with CRF, mean age 57 years (range 24 to 79 years) were randomized to 15 mg folic acid daily or placebo and followed for a median of 3.6 years. The primary intima-media thickness (IMT) and clinical end points were: rate of progression of mean maximum carotid IMT and a composite of myocardial infarction (MI), stroke, and cardiovascular death. Secondary end points included all cardiovascular events and change in pulse wave velocity, systemic arterial compliance and augmentation index. Data were analyzed by intention-to-treat.
RESULTS: Plasma total homocysteine was reduced by 19% in the folic acid group. There was no significant difference between the treatment groups in rate of change of IMT or any measure of artery function. Seventy-seven events occurred in the folic acid group (14.9 per 100 patient-years) as compared with 86 in the placebo group (16.3 per 100 patient-years). The rates of the primary and secondary clinical end points at five years were not significantly different after adjustment for baseline differences between the groups (adjusted hazard ratio for MI, stroke, and cardiovascular death: 0.98 [95% confidence interval: 0.66 to 1.47]; p = 0.94; for all cardiovascular events: 0.95 [95% confidence interval: 0.69 to 1.30]; p = 0.75).
CONCLUSIONS: High-dose folic acid does not slow atheroma progression or improve cardiovascular morbidity or mortality in patients with CRF.
|
Abbreviations and Acronyms
| | AIx = augmentation index | | ASFAST = Atherosclerosis and Folic Acid Supplementation Trial | | CI = confidence interval | | CRF = chronic renal failure | | GEE = generalized estimating equation | | IMT = intima-media thickness | | PWV = pulse wave velocity | | SAC = systemic arterial compliance | | tHcy = total plasma homocysteine |
|
This article has been cited by other articles:
|
|
|
|
 
J. F. E. Mann, P. Sheridan, M. J. McQueen, C. Held, J. M. O. Arnold, G. Fodor, S. Yusuf, E. M. Lonn, and on behalf of the HOPE-2 investigators
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study
Nephrol. Dial. Transplant.,
February 1, 2008;
23(2):
645 - 653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti
Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration
Nephrol. Dial. Transplant.,
November 1, 2007;
22(11):
3292 - 3297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Jamison, P. Hartigan, J. S. Kaufman, D. S. Goldfarb, S. R. Warren, P. D. Guarino, J. M. Gaziano, and For the Veterans Affairs Site Investigators
Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial
JAMA,
September 12, 2007;
298(10):
1163 - 1170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Hemmelgarn, B. J. Manns, J. Zhang, M. Tonelli, S. Klarenbach, M. Walsh, B. F. Culleton, and for the Alberta Kidney Disease Network
Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease
J. Am. Soc. Nephrol.,
March 1, 2007;
18(3):
993 - 999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Bazzano, K. Reynolds, K. N. Holder, and J. He
Effect of Folic Acid Supplementation on Risk of Cardiovascular Diseases: A Meta-analysis of Randomized Controlled Trials
JAMA,
December 13, 2006;
296(22):
2720 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
